Journal of NeuroVirology

, Volume 9, Issue 2, pp 205–221 | Cite as

Human immunodeficiency virus-associated dementia: An evolving disease

  • Justin C. McArthur
  • Norman Haughey
  • Suzanne Gartner
  • Kathy Conant
  • Carlos Pardo
  • Avi Nath
  • Ned Sacktor


This article reviews the changing epidemiology of HIV-associated dementia, current concepts of the different patterns of dementia under the influence of highly active antiretroviral therapy, and reviews therapeutic aspects.


brain cerebrospinal fluid cognitive impairment dementia HIV-1 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adamson DC, McArthur JC, Dawson TM, Dawson VL (1999). Rate and severity of HIV-associated dementia: corrleations with gp41 and iNOS. Mol Med 5: 98–109.PubMedGoogle Scholar
  2. Albert SM, Weber C, Todak G (1999). An observed performance test of medication management ability in HIV: relation to neuropsychological status and adherence outcomes. AIDS Behav 3: 121–128.Google Scholar
  3. Andrade A, Davis H, Celano S, Cheever L, Wu A, Skolasky RL, Letzt A, McArthur JC (2001). Intervention trial using a novel electronic device in HAART initiators: impact of cognitive dysfunction. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Feb 2—5, Chicago, IL.Google Scholar
  4. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, Leibowitch J (1997). Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease [see comments]. Science 277: 112–116.PubMedGoogle Scholar
  5. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, Moss A (2001). Nonadherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15: 1181–1183.PubMedGoogle Scholar
  6. Barker PB, Lee RR, McArthur JC (1995). AIDS dementia complex: evaluation with proton MR spectroscopic imaging. Radiology 195: 58–64.PubMedGoogle Scholar
  7. Bartlett JG, Gallant JE (2001). Medical management of HIV infection. Baltimore, MD: Johns Hopkins University, Division of Infectious Diseases.Google Scholar
  8. Bell JE, Busuttil A, Ironside JW, Rebus S, Donaldson YK, Simmonds P, Peutherer JF (1993). Human immunodeficiency virus and the brain: investigation of virus load and neuropathic changes in pre-AIDS subjects. J Infec Dis 168: 818–824.Google Scholar
  9. Berger JR, Avison MJ (2001). Diffusion tensor imaging in HIV infection: what is it telling us? AJNR Am J Neuroradiol 22: 237–238.PubMedGoogle Scholar
  10. Berger JR, Sheremata WA, Resnick L, Atherton S, Fletcher MA, Norenberg M (1989). Multiple sclerosis-like illness occurring with human immunodeficiency virus infection. Neurology 39: 324–329.PubMedGoogle Scholar
  11. Bouwman FH, Skolasky R, Hes D, Selnes OA, Glass JD, Nance-Sproson TE, Royal W, Dal Pan GJ, McArthur JC (1998). Variable progression of HIV-associated dementia. Neurology 50: 1814–1820.PubMedGoogle Scholar
  12. Brew BJ, Bhalla RB, Fleisher M, Paul M, Kahn A, Schwartz MK, Price RW (1989). Cerebrospinal fluid beta-2 microglobulin in patients infected with human immunodeficiency virus. Neurology 39: 830–834.PubMedGoogle Scholar
  13. Brew BJ, Bhalla RB, Paul M, Gallardo H, McArthur JC, Schwartz MK, Price RW (1990). Cerebrospinal fluid neopterin in human immunodeficiency virus type-I infection. Ann Neurol 28: 556–560.PubMedGoogle Scholar
  14. Brew BJ, Halman M, Catalan J, Sacktor N, Price RW, Brown S, Atkinson JH, Clifford DB, Simpson D, Torres G, Hall C, Power C, Marder K, Portegies P, McArthur JC, Symonds B, Romero C (2000). Abacavir in AIDS dementia complex: efficacy and lessons for future trials. Unpublished Work.Google Scholar
  15. Brew BJ, Pemberton L, Cunningham P, Law MG (1997). Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis 175: 963–966.PubMedGoogle Scholar
  16. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB (1997). Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 11: 1731–1738.PubMedGoogle Scholar
  17. Burton G, Keele B, Estes J, Thacker T, Gartner S (2002). Follicular dendritic cell contributions to HIV pathogenesis. Semin Immunol 14: 275.PubMedGoogle Scholar
  18. Chang L, Ernst T, Leonido-Yee M, Walot I, Singer E (1999). Cerebral metabolic abnormalities correlate with clinical severity of HIV-1 cognitive motor complex. Neurology 52: 100–108.PubMedGoogle Scholar
  19. Chang L, Rooney W, Carasig D, Tomasi D, Zhong K, Caparelli E, Zimmerman L, Ernst T (2002). Abnormal blood-brain barrier permeability in human immunodeficiency virus patients (abstract 282). In: Proceedings of American Neurological Association Meeting. October 13–16, New York.Google Scholar
  20. Chang L, Witt M, Eric M, Jovicich J, Ames N, Zhu W, Gaiefsky M, Ernst T (2001). Cerebral metabolite changes during the first nine months after HAART (abstract S63.001). Neurology 56: A474.Google Scholar
  21. Cherner M, Masliah E, Ellis RJ, Marcotte TD, Moore DJ, Grant I, Heaton RK (2002). Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 59: 1563–1567.PubMedGoogle Scholar
  22. Chiesi A, Seeber AC, Dally LG, Floridia M, Rezza G, Vella S (1996). AIDS dementia complex in the Italian National AIDS Registry: temporal trends (1987–1993) and differential incidence according to mode of transmission of HIV-1 infection. J Neurol Sci 144: 107–113.PubMedGoogle Scholar
  23. Childs EA, Lyles RH, Selnes OA, Chen B, Miller EN, Cohen BA, Becker JT, Mellors J, McArthur JC (1999). Plasma viral load and CD4 lympocytes predict HIV-associated dementia and sensory neuropathy. Neurology 52: 607–613.PubMedGoogle Scholar
  24. Chong WK, Paley M, Wilkinson ID, Hall-Craggs MA, Sweeney B, Harrison MJ, Miller RF, Kendall BE (1994). Localized cerebral proton MR spectroscopy in HIV infection and AIDS. AJNR Am J Neuroradiol 15: 21–25.PubMedGoogle Scholar
  25. Chong WK, Sweeney B, Wilkinson ID, Paley M, Hall-Craggs MA, Kendall BE, Shepard JK, Beecham M, Miller RF, Weller IVD, Newman SP, Harrison MJG (1993). Proton spectroscopy of the brain in HIV infection: correlation with clinical, immunologic, and MR imaging findings. Radiology 188: 119–124.PubMedGoogle Scholar
  26. Clifford DB, McArthur JC, Schifitto G, Kieburtz K, McDermott MP, Letendre S, Cohen BA, Marder K, Ellis RJ, Marra CM (2002a). A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology 59: 1568–1573.PubMedGoogle Scholar
  27. Clifford DB, McArthur JC, Schifitto G, Kieburtz K, McDermott MP, Letendre S, Cohen BA, Marder K, Ellis RJ, Marra CM (2002b). A randomized, placebocontrolled phase II clinical trial of CPI-1189 for HIV-associated motor-cognitive impairment. Neurology 59: 1568–1573.PubMedGoogle Scholar
  28. Cohen RA, Boland R, Paul R, Tashima KT, Schoenbaum EE, Celentano DD, Schuman P, Smith DK, Carpenter CC (2001). Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women. AIDS 15: 341–345.PubMedGoogle Scholar
  29. Conant K, McArthur JC, Griffin DE, Sjulson L, Wahl LM, Irani DN (1999). Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia [In Process Citation]. Ann Neurol 46: 391–398.PubMedGoogle Scholar
  30. Condra JH, Emini EA (1997). Preventing HIV-1 drug resistance. Sci Med 4: 14–23.Google Scholar
  31. Confort-Gouny S, Vion-Dury J, Nicoli F, Dano P, Gastaut JL, Cozzone PJ (1992). Metabolic characterization of neurological diseases by proton localized NMR spectroscopy of the human brain. C R Acad Sci III 315: 287–293.PubMedGoogle Scholar
  32. Corder EH, Robertson K, Lannfelt L, Bogdanovic N, Eggertsen G, Wilkins J, Hall C (1998). HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. Nat Med 4: 1182–1184.PubMedGoogle Scholar
  33. Cunningham PH, Smith DG, Satchell C, Cooper DA, Brew B (2000). Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS 14: 1949–1954.PubMedGoogle Scholar
  34. Dal Pan GJ, Glass JD, McArthur JC (1994). Clinicopathological correlations of HIV-1-associated vacuolar myelopathy: an autopsy-based case-control study. Neurology 44: 2159–2164.Google Scholar
  35. De Luca A, Ciancio BC, Larussa D, Murri R, Cingolani A, Rizzo MG, Giancola ML, Ammassari A, Ortona L (2002). Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals. Neurology 59: 342–347.PubMedGoogle Scholar
  36. Deeks SG, Abrams DI (1997). Genotypic-resistance assays and antiretroviral therapy. Lancet 349: 1489–1490.PubMedGoogle Scholar
  37. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM (2001). Virologic and immunologic consequences of discontinuing combination antiretroviraldrug therapy in HIV-infected patients with detectable viremia. N Eng J Med 344: 472–480.Google Scholar
  38. Donaldson YK, Bell JE, Ironside JW, Brettle RP, Robertson JR, Busuttil A, Simmonds P (1994). Redistribution of HIV outside the lymphoid system with onset of AIDS. Lancet 343: 382–385.Google Scholar
  39. Dougherty RH, Skolasky RL, McArthur JC (2002). Progression of HIV-associated dementia treated with HAART. AIDS Reader 12: 69–74.PubMedGoogle Scholar
  40. Dybul M, Chun T-W, Yoder C, Hidalgo B, Belson M, Hertogs K, Larder B, Dewar RL, Fox CH, Hallahan CW, Justement JS, Migueles SA, Metcalf JA, Davey RT, Daucher M, Pandya P, Baseler M, Ward DJ, Fauci AS (2001). Shortcycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci USA 98: 15161–15166.PubMedGoogle Scholar
  41. Ellis RJ, Gamst AC, Capparelli E, Spector SA, Hsia K, Wolfson T, Abramson I, Grant I, McCutchan JA (2000). Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources [In Process Citation]. Neurology 54: 927–936.PubMedGoogle Scholar
  42. Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR, Abramson I, Atkinson JH, Grant I, McCutchan JA, the HIV Neurobehavioral Research Center Group (1997). Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. Ann Neurol 42: 679–688.PubMedGoogle Scholar
  43. Ellis RJ, Moore DJ, Childers ME, Letendre S, McCutchan JA, Wolfson T, Spector SA, Hsia K, Heaton RK, Grant I (2002). Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol 59: 923–928.PubMedGoogle Scholar
  44. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A (2002). Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359: 30–36.PubMedGoogle Scholar
  45. Ferrando S, van Gorp W, McElhiney M, Goggin K, Sewell M, Rabkin J (1998). Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS 12: F65-F70.PubMedGoogle Scholar
  46. Filippi CG, Sze G, Farber SJ, Shahmanesh M, Selwyn PA (1998). Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy. Radiology 206: 491–498.PubMedGoogle Scholar
  47. Foudraine NA, Hoetelmans RM, Lange JM, de Wolf F, van Benthem BH, Maas JJ, Keet IP, Portegies P (1998). Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 351: 1547–1551.PubMedGoogle Scholar
  48. Furrer H, Egger M, Opravil M, Bernasconi E, Hirschel B, Battegay M, Telenti A, Vernazza P, Rickenbach M, Flepp M, Malinverni R, the Swiss HIV Cohrot Study (1999). Discontinuation of primary prophylaxis against pneumocystis carinii penumonia in HIV-1-infected adults treated with combination antiretroviral therapy. N Eng J Med 340: 1301–1306.Google Scholar
  49. Gartner S (2000). HIV infection and dementia [see comments]. Science 287: 602–604.PubMedGoogle Scholar
  50. Gartner S, Liu Y (2002). Insights into the role of immune activation in HIV neuropathogenesis. J NeuroVirol 8: 69–75.PubMedGoogle Scholar
  51. Gartner S, Liu Y, Hunter E, Sacktor N, Conant K, Pardo C, Mc Arthur J (2000). Role of systemic events in the development of HIV encephalitis and dementia. Presented at 3rd International Symposium on Neurovirology. San Francisco, Sept 14–16.Google Scholar
  52. Glass JD, Fedor H, Wesselingh SL, McArthur JC (1995). Immunocytochemical quantitation of HIV in the brain: correlations with HIV-associated dementia. Ann Neurol 38: 755–762.PubMedGoogle Scholar
  53. Glass JD, Wesselingh SL, Selnes OA, McArthur JC (1993). Clinical-neuropathologic correlation in HIV-associated dementia. Neurology 43: 2230–2237.PubMedGoogle Scholar
  54. Gonzalez E, Dhanda R, Bamshad M, Mummidi S, Geevarghese R, Catano G, Anderson SA, Walter EA, Stephan KT, Hammer MF, Mangano A, Sen L, Clark RA, Ahuja SS, Dolan MJ, Ahuja SK (2001). Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci USA 98: 5199–5204.PubMedGoogle Scholar
  55. Gonzalez E, Rovin BH, Sen L, Cooke G, Dhanda R, Mummidi S, Kulkarni H, Bamshad MJ, Telles V, Anderson SA, Walter EA, Stephan KT, Deucher M, Mangano A, Bologna R, Ahuja SS, Dolan MJ, Ahuja SK (2002). HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci USA 99: 13795–13800.PubMedGoogle Scholar
  56. Griffin DE (1997). Cytokines in the brain during viral infection: clues to HIV-associated dementia. J Clin Invest 100: 2948–2951.PubMedGoogle Scholar
  57. Griffin DE, McArthur JC, Cornblath DR (1991). Neopterin and interferon-gamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease. Neurology 41: 69–74.PubMedGoogle Scholar
  58. Griffin DE, Wesselingh SL, McArthur JC (1994). Elevated central nervous system prostaglandins in HIV-associated dementia. Ann Neurol 35: 592–597.PubMedGoogle Scholar
  59. Groothuis DR, Levy RM (1997). The entry into antiviral and antiretroviral drugs into the central nervous system. J NeuroVirol 3: 387–400.PubMedGoogle Scholar
  60. Hahn MK, Blakely RD (2002). Monoamine transporter gene structure and polymorphisms in relation to psychiatric and other complex disorders. Pharmacogenomics J 2: 217–235.PubMedGoogle Scholar
  61. Heseltine PNR, Goodkin K, Atkinson JH, Vitiello B, Rochon J, Heaton RK, Eaton EM, Wilkie FL, Sobel E, Brown SJ, Feaster D, Schneider L, Goldschmidts WL, Stover ES (1998). Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch Neurol 55: 41–51.PubMedGoogle Scholar
  62. Heyes MP, Brew BJ, Martin A, Price RW, Salazar AM, Sidtis JJ, Yergey JA, Mouradian MM, Sadler AE, Keilp J, Rubinow D, Markey SP (1991). Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurologic status. Ann Neurol 29: 202–209.PubMedGoogle Scholar
  63. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123–126.PubMedGoogle Scholar
  64. Hogervorst E, Jurriaans S, Dewolf F, Van Wijk A, Wiersma A, Valk M, Roos M, Vangemen B, Coutinho R, Miedema F, Goudsmit J (1995). Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection. Low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infec Dis 171: 811–821.Google Scholar
  65. Hriso E, Kuhn T, Masdeu JC, Grundman M (1991). Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am J Psychiatry 148: 1558–1561.PubMedGoogle Scholar
  66. Janssen RS, Nwanyanwu OC, Selik RM, Stehr-Green JK (1992). Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology 42: 1472–1476.PubMedGoogle Scholar
  67. Janssen RS, Saykin AJ, Cannon L, Campbell J, Pinsky PF, Hessol NA, O’Malley PM, Lifson AR, Doll LS, Rutherford GW, et al (1989). Neurological and neuropsychological manifestations of HIV-1 infection: association with AIDS-related complex but not asymptomatic HIV-1 infection. Ann Neurol 26: 592–600.PubMedGoogle Scholar
  68. Jarvik JG, Lenkinski RE, Grossman RI, Gomori JM, Schnall MD, Frank I (1993). Proton MR spectroscopy of HIV-infected patients: characterization of abnormalities with imaging and clinical correlation. Radiology 186: 739–744.PubMedGoogle Scholar
  69. Johnson RT, McArthur JC, Narayan O (1988). The neurobiology of human immunodeficiency virus infections. FASEB J 2: 2970–2981.PubMedGoogle Scholar
  70. Joint United Nations Program on HIV/AIDS (2001). AIDS epidemic update—December 2001. Geneva. UNAIDS and the World Health Organization.Google Scholar
  71. Keswani S, Pardo CA, Cherry CL, Hoke A, McArthur JC (2002). HIV-associated sensory neuropathies. AIDS 16: 1–13.Google Scholar
  72. Khanna KV, Yu XF, Ford DH, Ratner L, Hildreth JK, Markham RB (2000). Differences among HIV-1 variants in their ability to elicit secretion of TNF-alpha. J Immunol 164: 1408–1415.PubMedGoogle Scholar
  73. Kibayashi K, Mastri AR, Hirsch CS (1996). Neuropathology of human immunodeficiency virus infection at different disease stages. Hum Pathol 27: 637–642.PubMedGoogle Scholar
  74. Langford TD, Letendre SL, Marcotte TD, Ellis RJ, McCutchan JA, Grant I, Mallory ME, Hansen LA, Archibald S, Jernigan T, Masliah E (2002). Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS 16: 1019–1029.PubMedGoogle Scholar
  75. Liu Y, Tang XP, McArthur JC, Scott J, Gartner S (2000). Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain. J NeuroVirol 6(Suppl 1): S70-S81.PubMedGoogle Scholar
  76. Lucas GM, Gebo KA, Chaisson RE, Moore RD (2002). Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 16: 767–774.PubMedGoogle Scholar
  77. Maher J, Choudhri S, Halliday W, Power C, Nath A (1997). AIDS dementia complex with generalized myoclonus. Mov Disord 12: 593–597.PubMedGoogle Scholar
  78. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT (2002). Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359: 727–732.PubMedGoogle Scholar
  79. Marcotte TD, Heaton RK, Wolfson T, Taylor MJ, Alhassoon O, Arfaa K, Ellis RJ, Grant I (1999). The impact of HIV-related neuropsychological dysfunction on driving behavior. The HNRC Group. J Int Neuropsychol Soc 5: 579–592.PubMedGoogle Scholar
  80. Marder K, Albert S, McDermott MP, McArthur JC, Schifitto G, Selnes OA, Sacktor N, Stern Y, Palumbo D, Kieburtz K, Cohen B, Orme C, Epstein L (2003). Inter-rater reliability of the Memorial Sloan Kettering staging of HIV-associated cognitive impairment. Neurology (in press).Google Scholar
  81. Marra CM (1999). Bacterial and fungal brain infections in AIDS. Semin Neurol 19: 177–184.PubMedGoogle Scholar
  82. Marra CM, Coombs RW, Collier AC (1999). Changes in CSF and plasma HIV-1 RNA and in neuropsychological test performance after starting HAART (abstract 408). Present at 6th Conference on Retroviruses and Opportunistic infections, Chicago, Jan 31–Feb 4.Google Scholar
  83. Mayeux R, Stern Y, Tang MX, Todak G, Marder K, Sano M, Stein Z, Ehrhardt AA, Gorman JM (1993). Mortality risks in gay men with human immunodeficiency virus infection and cognitive impairment. Neurology 43: 176–182.PubMedGoogle Scholar
  84. McArthur JC (1987). Neurologic manifestations of AIDS. Medicine (Baltimore) 66: 407–437.Google Scholar
  85. McArthur JC, Enger C, Jacobson L, Gore ME, Miller EN, Cohen BA, Becker JT, Kleeberger C, Kaslow R (1999a). Influence of human major histocompatibility complex genes on the development of HIV-associated dementia (abstract). Presented at American Neurological Association Meeting, Seattle, Oct 19.Google Scholar
  86. McArthur JC, Hoover DR, Bacellar H, Miller EN, Cohen BA, Becker JT, Graham NMH, McArthur JH, Selnes OA, Jacobson LP, Visscher BR, Concha M, Saah A (1993). Dementia in AIDS patients: incidence and risk factors. Neurology 43: 2245–2252.PubMedGoogle Scholar
  87. McArthur JC, McClernon DR, Cronin MF, Nance-Sproson TE, Saah AJ, St Clair M, Lanier ER (1997). Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 42: 689–698.PubMedGoogle Scholar
  88. McArthur JC, McClernon DR, Nance-Sproson L, Skolasky R, Lanier R (1999b). Factors associated with durable suppression of HIV in the cerebrospinal fluid (abstract P03.005). Neurology 52: A191.Google Scholar
  89. McArthur JC, McDermott MP, McClernon D, St.Hillaire C, Conant K, Marder K, Schifitto G, Selnes OA, Sacktor N, Stern Y, Albert S, Palumbo D, Kieburtz K, deMarcaida JA, Cohen B, Epstein LG (2002). Attenuated CNS infection and immune activation in advanced HIV/AIDS. Unpublished work.Google Scholar
  90. McClernon DR, Lanier R, Gartner S, Feaser P, Pardo CA, St Clair M, Liao Q, McArthur JC (2001). HIV in the brain: RNA levels and patterns of zidovudine resistance. Neurology 57: 1396–1401.PubMedGoogle Scholar
  91. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D (1994). Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 371: 508–510.PubMedGoogle Scholar
  92. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR (1997). Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126: 946–954.PubMedGoogle Scholar
  93. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA (1996). Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272: 1167–1170.PubMedGoogle Scholar
  94. Menon DK, Ainsworth JG, Cox IJ, Coker RC, Sargentoni J, Coutts GA, Baudouin CJ, Kocsis AE, Harris JRW (1992). Proton MR spectroscopy of the brain in AIDS dementia complex. J Comput Assist Tomogr 16: 538–542.PubMedGoogle Scholar
  95. Menon DK, Baudouin CJ, Tomlinson D, Hoyle C (1990). Proton MR spectroscopy and imaging of the brain in AIDS: evidence of neuronal loss in regions that appear normal with imaging. J Comput Assist Tomogr 14: 882–885.PubMedGoogle Scholar
  96. Miller EN, Selnes OA, McArthur JC, Satz P, Becker JT, Cohen BA, Sheridan K, Machado AM, Van Gorp WG, Visscher B (1990). Neuropsychological performance in HIV-1 infected homosexual men: The Multicenter AIDS Cohort Study (MACS). Neurology 40: 197–203.PubMedGoogle Scholar
  97. Mirsattari SM, Power C, Nath A (1998). Parkinsonism with HIV infection. Mov Disord 13: 684–689.PubMedGoogle Scholar
  98. Moore RD, Wong W-M, Keruly JC, McArthur JC (2000). Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine, and hydroxyurea. AIDS 14: 273–278.PubMedGoogle Scholar
  99. Nath A, Anderson C, Jones M, Maragos W, Booze R, Mactutus C, Bell J, Hauser KF, Mattson M (2000). Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol 14: 222–227.PubMedGoogle Scholar
  100. Navia BA, Dafni U, Simpson D, Tucker T, Singer E, McArthur JC, Yiannoutsos C, Zaborski L, Lipton SA, The AIDS Clinical Trials Group (1998). A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology 51: 221–228.PubMedGoogle Scholar
  101. Navia BA, Jordan BD, Price RW (1986). The AIDS dementia complex: I. Clinical features. Ann Neurol 19: 517–524.PubMedGoogle Scholar
  102. Palella FJJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators [see comments]. N Engl J Med 338: 853–860.PubMedGoogle Scholar
  103. Pang S, Koyanagi Y, Miles S, Wiley C, Vinters HV, Chen IS (1990). High levels of unintegrated HIV-1 DNA in brain tissue of AIDS dementia patients. Nature 343: 85–89.PubMedGoogle Scholar
  104. Pardridge WM (2002). Targeting neurotherapeutic agents through the blood-brain barrier. Arch Neurol 59: 35–40.PubMedGoogle Scholar
  105. Paterson D, Swindells S, Mohr J, Brester M, Vergis E, Souier C, Wagener M, Singh N (2002). Adherence to protease inhibitor therapy in patients with HIV infection. Am Intern Med 136: 253.Google Scholar
  106. Powderly WG, Landay A, Lederman MM (1998). Recovery of the immune system with antiretroviral therapy: the end of opportunism [Review] JAMA 280: 72–77.PubMedGoogle Scholar
  107. Power C, McArthur JC, Johnson RT, Perryman S, Glass JD, Chesebro B (1993). Distinct envelope sequences associated with HIV dementia. Presented at the First National Conference on Human Retroviruses and Related Infections, Washington DC, Dec 12–16.Google Scholar
  108. Power C, McArthur JC, Nath A, Wehrly K, Mayne M, Nishio J, Langelier T, Johnson RT, Chesebro B (1998). Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients. J Virol 72: 9045–9053.PubMedGoogle Scholar
  109. Price DL, Tanzi RE, Borchelt DR, Sisodia SS (1998). Alzheimer’s disease: genetic studies and transgenic models. Annu Rev Genet 32: 461–493.PubMedGoogle Scholar
  110. Price RW, Paxinos EE, Grant RM, Drews B, Nilsson A, Hoh R, Hellmann NS, Petropoulos CJ, Deeks SG (2001a). Cerebrospinal fluid response to structured treatment interruption after virological failure. AIDS 15: 1251–1259.PubMedGoogle Scholar
  111. Price RW, Paxinos EE, Grant RM, Drews B, Nilsson A, Hoh R, Hellmann NS, Petropoulos CJ, Deeks SG (2001b). Cerebrospinal fluid response to structured treatment interruption after virological failure. AIDS 15: 1251–1259.PubMedGoogle Scholar
  112. Price RW, Sidtis JJ (1990). Evaluation of the AIDS dementia complex in clinical trials. J Acquir Immunodefic Syndr 3(Suppl 2): S51-S60.Google Scholar
  113. Price RW, Yiannoutsos CT, Clifford DB, Zaborski L, Tselis A, Sidtis JJ, Cohen B, Hall CD, Erice A, Henry K (1999). Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. AIDS 13: 1677–1685.PubMedGoogle Scholar
  114. Pulliam L, Gascon R, Stubblebine M, McGuire D, McGrath MS (1997). Unique monocyte subset in patients with AIDS dementia. Lancet 349: 692–695.PubMedGoogle Scholar
  115. Quasney MW, Zhang Q, Sargent S, Mynatt M, Glass J, McArthur J (2001). Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia. Ann Neurol 50: 157–162.PubMedGoogle Scholar
  116. Race EM, Adelson-Mitty J, Kriegel GR, Barlam TF, Reimann KA, Letvin NL, Japour AJ (1998). Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease [see comments]. Lancet 351: 252–255.PubMedGoogle Scholar
  117. Reyes MG, Faraldi F, Senseng CS, Flowers C, Fariello R (1991). Nigral degeneration in acquired immune deficiency syndrome (AIDS). Acta Neuropathol 82: 39–44.PubMedGoogle Scholar
  118. Roederer M (1998). Getting to the HAART of T cell dynamics [news; comment]. Nat Med 4: 145–146.PubMedGoogle Scholar
  119. Sabato S, Wesselingh S, Fuller A, Ray J, Mijch A (2002). Efavirenz-induced catatonia. AIDS 16: 1841–1842.PubMedGoogle Scholar
  120. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, Becker JT, Cohen B, McArthur JC (2001a). HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990–1998. Neurology 56: 257–260.PubMedGoogle Scholar
  121. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L (2002). HIV-associated cognitive impairment before and after the advent of combination therapy. J NeuroVirol 8: 136–142.PubMedGoogle Scholar
  122. Sacktor N, Schifitto G, McDermott MP, Marder K, McArthur JC, Kieburtz K (2000a). Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebocontrolled study. Neurology 54: 233–235.PubMedGoogle Scholar
  123. Sacktor N, Tarwater PM, Skolasky RL, McArthur JC, Selnes OA, Becker J, Cohen B, Miller EN (2001b). CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing. Neurology 57: 542–544.PubMedGoogle Scholar
  124. Sacktor NC, Bacellar H, Hoover DR, Nance-Sproson TE, Selnes OA, Miller EN, Dal Pan GJ, Kleeberger C, Brown A, Saah A, McArthur JC (1996). Psychomotor slowing in HIV infection. A predictor of dementia, AIDS, and death. J NeuroVirol 2: 404–410.PubMedGoogle Scholar
  125. Sacktor NC, McArthur JC (1997). Prospects for therapy of HIV-associated neurologic disease. J NeuroVirol 3: 89–101.PubMedGoogle Scholar
  126. Sacktor NC, Skolasky RL, Lyles RH, Esposito D, Selnes OA, McArthur JC (2000b). Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors. J NeuroVirol 6: 84–88.PubMedGoogle Scholar
  127. Schaner ME, Gerstin KM, Wang J, Giacomini KM (1999). Mechanisms of transport of nucleosides and nucleoside analogues in choroid plexus. Adv Drug Deliv Rev 39: 51–62.PubMedGoogle Scholar
  128. Schifitto G, Kieburtz K, McDermott MP, McArthur J, Marder K, Sacktor N, Palumbo D, Selnes O, Stern Y, Epstein L, Albert S (2001). Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomes. Neurology 56: 415–418.PubMedGoogle Scholar
  129. Schifitto G, Sacktor N, Marder K, McDermott MP, McArthur JC, Kieburtz K, Small S, Epstein LG, the Neurologic AIDS Research Consortium (1999). Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurology 53: 391–396.PubMedGoogle Scholar
  130. Schooley RT (1995). Correlation between viral load measurements and outcome in clinical trials of antiviral drugs. AIDS 9(Suppl 2): S15-S19.PubMedGoogle Scholar
  131. Sepkowitz KA (2001). AIDS-the first 20 years. N Engl J Med 344: 1764–1772.PubMedGoogle Scholar
  132. Shapiro MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, Perlman JF, Athey LA, Keesey JW, Goldman DP, Berry SH, Bozzette SA (1999). Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA 281: 2305–2315.PubMedGoogle Scholar
  133. Shaw GM, Harper ME, Hahn BH, Epstein LG, Gajdusek DC, Price RW, Navia BA, Petito CK, O’Hara CJ, Groopman JE, et al (1985). HTLV-III infection in brains of children and adults with AIDS encephalopathy. Science 227: 177–182.PubMedGoogle Scholar
  134. Sidtis JJ, Gatsonis C, Price RW, Singer EJ, Collier AC, Richman DD, Hirsch MS, Schaerf FW, Fischl MA, Kieburtz K, Simpson D, Koch MA, Feinberg J, Dafni R, AIDS Clinical Trials Group (1993). Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. Ann Neurol 33: 343–349.PubMedGoogle Scholar
  135. Sinclair E, Gray F, Ciardi A, Scaravilli F (1994). Immunohistochemical changes and PCR detection of HIV provirus DNA in brains of asymptomatic HIV-positive patients. J Neuropathol Exp Neurol 53: 43–50.PubMedGoogle Scholar
  136. Sinclair E, Gray F, Scaravilli F (1992). PCR detection of HIV proviral DNA in the brain of an asymptomatic HIV-positive patient (letter). J Neurol 239: 469–470.PubMedGoogle Scholar
  137. Sinclair E, Scaravilli F (1992). Detection of HIV proviral DNA in cortex and white matter of AIDS brains by nonisotopic polymerase chain reaction: correlation with diffuse poliodystrophy. AIDS 6: 925–932.PubMedGoogle Scholar
  138. Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL (1996). Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care 8: 261–269.PubMedGoogle Scholar
  139. Tagliati M, Simpson D, Morgello S, Clifford D, Schwartz RL, Berger JR (1998). Cerebellar degeneration associated with human immunodeficiency virus infection. Neurology 50: 244–251.PubMedGoogle Scholar
  140. Takahashi K, Wesselingh SL, Griffin DE, McArthur JC, Johnson RT, Glass JD (1996). Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol 39: 705–711.PubMedGoogle Scholar
  141. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders (1998). A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virusassociated cognitive impairment. Neurology 50: 645–651.Google Scholar
  142. The Dana Consortium on Therapy of HIV Dementia and Related Cognitive Disorders (1997). Safety and efficacy of the antioxidant OPC-14117 in HIV associated cognitive impairment. Neurology 49: 142–146.Google Scholar
  143. Thomas SA, Segal MB (1997). The passage of azidodeoxythymidine into and within the central nervous system: does it follow the parent compound, thymidine? J Pharmacol Exp Ther 281: 1211–1218.PubMedGoogle Scholar
  144. Thompson KA, McArthur JC, Wesselingh SL (2001). Correlation between disease progression and astrocyte apoptosis in HIV-associated dementia. Ann Neurol 49: 745–752.PubMedGoogle Scholar
  145. Tozzi V, Balestra P, Galgani S, Narciso P, Ferri F, Sebastiani G, D’Amato C, Affricano C, Pigorini F, Pau FM, De Felici A, Benedetto A (1999). Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS 13: 1889–1897.PubMedGoogle Scholar
  146. Tsao BP (2002). the genetics of human lupus. In: Dubois’ lupus erythematosus. Wallace DJ, Hahn BH (eds). Philadelphia: William & Wilkens, pp 97–120.Google Scholar
  147. Tyler KL, McArthur JC (2002). Through a glass, darkly: cerebrospinal fluid viral load measurements and the pathogenesis of human immunodeficiency virus infection of the central nervous system. Arch Neurol 59: 909–912.PubMedGoogle Scholar
  148. Tyor WR, Griffin JW, Wesselingh S, McArthur JC, Griffin DE (1995). A unifying hypothesis for the pathogenesis of HIV-associated dementia complex, vacuolar myelopathy, and sensory neuropathy. J Acquir Immunodefic Syndr 9: 379–388.Google Scholar
  149. UNAIDS (2000). AIDS Epidemic: update, December 2000. Geneva: Joint United Nations Programme on HIV/AIDS.Google Scholar
  150. Valcour V, Shiramizu B, Shikuma C, Poff P, Watters M, Grove J, Selnes O, Sacktor N (2002). Neurocognitive function among older compared to younger HIV-1 seropositive individuals [Abstract]. J NeuroVirol 8: 69.Google Scholar
  151. Weinshenker BG, Santrach P, Bissonet AS, McDonnell SK, Schaid D, Moore SB, Rodriguez M (1998). Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology 51: 742–747.PubMedGoogle Scholar
  152. Weinshenker BG, Wingerchuk DM, Liu Q, Bissonet AS, Schaid DJ, Sommer SS (1997). Genetic variation in the tumor necrosis factor alpha gene and the outcome of multiple sclerosis. Neurology 49: 378–385.PubMedGoogle Scholar
  153. Wendell KA, McClernon DR, Lanier ER, McArthur JC (2001). Discordant HIV-1 drug resistance mutations in paired CSF and plasma. Presented at the Infectious Disease Society of America Meeting, San Francisco, Oct 25–28.Google Scholar
  154. Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJ, Richman DD (1997). In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissue. J Virol 71: 2059–2071.PubMedGoogle Scholar
  155. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Vol-berding PA (2002). Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 288: 222–235.PubMedGoogle Scholar
  156. Yiannoutsos C (2002). Patterns of regional brain metabolism and diagnostic utility of proton MRS in AIDS dementia complex. Unpublished work.Google Scholar
  157. Zink MC, Coleman GD, Mankowski JL, Adams RJ, Tarwater PM, Fox K, Clements JE (2001). Increased macrophage chemoattractant protein-1 in cerebrospinal fluid precedes and predicts simian immunodeficiency virus encephalitis. J Infect Dis 184: 1015–1021.PubMedGoogle Scholar
  158. Zink MC, Suryanarayana K, Mankowski JL, Shen A, Piatak M, Jr., Spelman JP, Carter DL, Adams RJ, Lifson JD, Clements JE (1999). High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol 73: 10480–10488.PubMedGoogle Scholar

Copyright information

© Journal of NeuroVirology, Inc. 2003

Authors and Affiliations

  • Justin C. McArthur
    • 1
  • Norman Haughey
    • 1
  • Suzanne Gartner
    • 1
  • Kathy Conant
    • 1
  • Carlos Pardo
    • 1
  • Avi Nath
    • 1
  • Ned Sacktor
    • 1
  1. 1.HIV Neurology Program, Johns Hopkins University School of MedicineThe Johns Hopkins UniversityBaltimoreUSA

Personalised recommendations